Sentences with phrase «uveal melanoma»

The incidence of uveal melanoma in Europe follows a gradient from the north to the south: 2 to 8 new cases per one million population, annually.

One hundred and one patients with metastatic uveal melanoma at 15 centers in the United States and Canada were randomized to receive either selumetinib or standard chemotherapy.

This pathway is activated by mutations in the Gnaq and Gna11 genes, which occur in more than 85 percent of uveal melanoma patients; 84 percent of patients in this trial had one of the mutations.

«This is the first study to show that a systemic therapy provides significant clinical benefit in a randomized fashion to advanced uveal melanoma patients, who have very limited treatment options,» said Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan - Kettering and lead author on the study.

In experiments with mice, the UC San Diego - led team showed that verteporfin also suppresses the growth of uveal melanoma tumors derived from human tumors.

The researchers looked specifically at uveal melanoma.

High - risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumours, and Uveal Melanoma across GenoMEL

In the USA 5 / million population are affected by uveal melanoma annually.

Scientists have long suspected a genetic association with uveal melanoma because one of two gene mutations is present in approximately 70 percent of all tumors.

An untreated uveal melanoma tumor (left) covers entire eye of a mouse.

But uveal melanoma often spreads to the liver, and determining the metastatic status of the disease can be difficult.

In cases of uveal melanoma metastasis, patients typically succumb within two to eight months after diagnosis.

Dr. Schwartz and others subsequently demonstrated that inhibition of MEK, a key enzyme in the MAPK pathway, can inhibit the growth of uveal melanoma cells in the laboratory.

Though uveal melanoma is rare — there are only 2,500 cases diagnosed in the United States each year — about half of patients will develop metastatic disease, and survival for patients with advanced disease has held steady at nine months to a year for decades.

Uveal melanoma does not respond to the drugs given to patients with melanoma on the skin; and, in fact, there is no drug approved specifically for treatment of the disease.

Patients with uveal melanoma receive surgery to remove the tumor — and in some advanced cases, the entire eye — as well as radiation therapy or chemotherapy.

About 1,500 cases of uveal melanoma occur in the United States each year, usually among older adults.

Furthermore, this compound displayed promising properties by impairing CXCR4 function in three mouse models: paw inflammation, Matrigel plug angiogenesis, and uveal melanoma micrometastasis.

Uveal melanomas represent 3 - 5 % of all melanomas.

While an in - house (MH Stern's team) developed technique (biPAP - PCR) showed exquisite sensitivity for uveal melanoma mutations (Madic, Clin Cancer Res 2012), we developed other ctDNA techniques (ddPCR and NGS - based techniques).

Sarah Hummel - «Neuromuscular Junction Disease in a 1 - year - old Mixed Breed Dog» Nicholas Milano - «Osteonecrosis of the Jaw in a Cocker Spaniel» Kevin Mu - «Malignant Uveal Melanoma in a 12 year old Labrador Retriever» Carly Augustyn - «Tibial Plateau Leveling Osteotomy in a 4 - year - old Domestic Shorthair Cat» Ashley Newman - Moderator

In the trial, researchers randomized 98 patients with metastatic uveal melanoma and administered selumetinib to 47, of which 81 percent had a Gnaq or Gna11 mutation.

«If we can confirm selumetinib's effectiveness in treating advanced uveal melanoma in this follow - up trial, it will become the standard therapy for this disease, forming a foundation for new drug combinations that could maximize selumetinib's MEK - inhibitor effect,» he said.

Ocular cancers, such as uveal melanoma or ciliary body adenoma or carcinoma, are another contributing condition to uveitis.

High - risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumours, and Uveal Melanoma across GenoMEL Goldstein et al..

Because of this biological and prognostic importance in cutaneous melanoma, angiotropism was studied in uveal melanoma (UM).

Research teams focused on both cutaneous and uveal melanoma are fast - tracking discoveries into the clinical setting, and bringing novel therapeutic options to patients in the Philadelphia region,» said Karen Knudsen, Director of the Sidney Kimmel Cancer Center.

As with melanoma skin cancer, uveal melanoma is a malignancy of these melanin - producing cells.

Approximately 2,000 people in the United States are diagnosed with uveal melanoma each year.

Uveal melanoma (which is biologically distinct from skin melanoma) arises from the uvea's melanocytes, the pigment cells that give the eye its color.

The median survival rate for patients with metastatic uveal melanoma is 12 months.

Uveal melanoma is a cancer of the iris, ciliary body, or choroid — structures in the eye collectively known as the uvea.

For the first time, a therapy has been found that can delay progression of metastatic uveal melanoma, a rare and deadly form of melanoma of the eye.

Several years ago, researchers found that 80 percent of patients with uveal melanoma had mutations to GNAQ or GNA11, genes that activate signals in the mitogen - activated protein kinase (MAPK) pathway.

In one of the balancing acts of medicine, the anti-inflammatory action of the drug also increases the risk for other conditions, in this case, a rare form of eye cancer, uveal melanoma.

Dr. Schwartz thinks that treatment of uveal melanoma will ultimately involve rational drug design and a combination of drugs, similar to the approach used to combat HIV infection.

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan - Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).